Cryopreservation has long been only partially and inconsistently achieved using agents that both mitigate ice crystal formation and buffer osmotic changes upon freeze-thaw events. Our scientists at Evergreen pioneered a new line of investigation to understand the intracellular mechanisms behind cellular freeze-thaw shock. Our patent-pending technology reveals a novel significance behind the role of recently discovered biological pathways in this process, and uses a pharmaceutical approach to greatly enhance post-thaw functionality.
This schematic from global cell supplier ATCC highlights the fate of cryopreserved cells, which are typically exposed to 10% DMSO just before the freezing process begins. DMSO is highly toxic to cells and therefore cell exposure must be minimized outside of the frozen state. DMSO also has been shown to cause epigenetic changes to cells, posing further risks to genomic integrity.
Cells protected with Everlast® are pharmaceutically targeted to prevent stress pathways induced by freeze-thaw events, and emerge healthier and more functional than cells cryopreserved with DMSO.
the use of cellular materials and significantly enable scientific research and medical advances through commercialized cryopreservation of cells and organs, with immediate focus on use in Genetically Engineered Cells (GECs™) from mouse disease models, as well as human cell therapeutics.
Everlast provides cells with significantly improved consistency of performance across thaw events, as shown here. Percent error of performance for each thaw event shown comparing Everlast (green dots) to DMSO (blue dots), where the line (white) indicates perfect performance, which measures viability, cell size and 3-day functionality tests in culture.